A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin
about
Lipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinomaSuppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCKPolyoxomolybdate Bisphosphonate Heterometallic Complexes: Synthesis, Structure, and Activity on a Breast Cancer Cell Line.Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometriesIn Vitro and In Vivo Investigation of the Inhibition of Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Structures of Trypanosome Vacuolar Soluble Pyrophosphatases: Antiparasitic Drug TargetsRole of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer.Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis.Isoprenoid Biosynthesis Inhibitors Targeting Bacterial Cell Growth.Combining Vγ9Vδ2 T Cells with a Lipophilic Bisphosphonate Efficiently Kills Activated Hepatic Stellate Cells.Anticancer Activity of Polyoxometalate-Bisphosphonate Complexes: Synthesis, Characterization, In Vitro and In Vivo Results.A large-scale RNA interference screen identifies genes that regulate autophagy at different stages.Head-to-Head Prenyl Synthases in Pathogenic Bacteria.Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways.
P2860
Q28606634-7F082D34-5B06-4DF1-B24B-51A4ECBFBDA2Q28833740-258DE955-A7B6-4E18-8910-48D24D0B86EAQ30971976-7FCD7CBE-7167-4D64-9618-65B7B2D82C62Q35178883-762C9614-85C3-49CE-AC76-1F0236C99D7AQ35782846-A96D61CF-6BA1-4CF7-A093-6B8AB61171BBQ36398735-63936680-6D98-4E40-A81D-C01A5C4E8E42Q36922274-0F89E8DA-2297-43BB-9F63-5D633CC40A83Q37690890-001806A0-9243-4029-A2F4-2343B134DD6CQ39138688-36662641-DB7F-42E2-9707-9DE1DC1BB24CQ41162635-534BB82B-072A-43D4-A6B9-FF6628FC375AQ41913607-948FFB14-C3A4-41FD-8405-8C378A5B6D47Q42351008-1CF8E387-9FFF-4153-A7B9-05F12CE7ABBEQ47146669-4CF5408C-645A-457B-85FC-0EDFEC24116FQ48059346-8F64F690-0FA8-41D6-B23E-53DB4633F212Q50055572-F5887834-DFC1-4195-AE9C-7076C75DF153Q50946882-3E520251-C4A8-45D4-8620-C53C438BD335Q54978574-F8F4F48B-01F2-4912-85BB-2B064150C352
P2860
A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A combination therapy for KRAS ...... bisphosphonates and rapamycin
@ast
A combination therapy for KRAS ...... bisphosphonates and rapamycin
@en
type
label
A combination therapy for KRAS ...... bisphosphonates and rapamycin
@ast
A combination therapy for KRAS ...... bisphosphonates and rapamycin
@en
prefLabel
A combination therapy for KRAS ...... bisphosphonates and rapamycin
@ast
A combination therapy for KRAS ...... bisphosphonates and rapamycin
@en
P2093
P2860
P1476
A combination therapy for KRAS ...... bisphosphonates and rapamycin
@en
P2093
Eric Oldfield
Francisco Guerra
Inder M Verma
Narayana Yeddula
William Low
Wolfgang Fischer
Xiaoying Zhou
Yi-Liang Liu
P2860
P304
P356
10.1126/SCITRANSLMED.3010382
P407
P577
2014-11-01T00:00:00Z